November 09th, 2018

MedDay Pharmaceuticals Announces Full Patient Enrollment for MD1003 Phase III Clinical Trial (SPI2) in Progressive Multiple Sclerosis
Read more

July 26th, 2018

MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer
Read more
See all recent news
October 16 2017

MedDay to Participate in the 7th Joint ECTRIMS – ACTRIMS Meeting in Paris, France

September 18 2017

MedDay Pharmaceuticals GmbH to participate at the 90th Congress of the German Society of Neurology in Leipzig, Germany

May 25 2016

MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial

April 27 2015

MedDay to webcast results of its pivotal Phase III study of MD1003 in patients with Progressive Multiple Sclerosis

See all events